HIV antibody trial results offer 'proof of concept'

Hutch News Stories | Sabin Russell | Jan. 26, 2021


Vaccines stop COVID-19 symptoms, but do they stop transmission?

Hutch News Stories | Sabin Russell | Dec. 16, 2020

Fred Hutch statement on the interim analysis of the Phase 3 trial of the Moderna vaccine against COVID-19

Hutch News Releases | Nov. 16, 2020

Fred Hutch statement on Phase 3 vaccine interim analysis of Pfizer/ BioNTech vaccine candidate

Hutch News Releases | Nov. 9, 2020

CoVPN team leads campaign to ensure diversity in COVID-19 vaccine trials

Hutch News Stories | FRED HUTCH NEWS SERVICE STAFF | Sept. 29, 2020 

Fred Hutch joins international COVID-19 vaccine effort

Hutch News Releases | July 8, 2020

Q&A: Dr. Larry Corey at the center of COVID-19 vaccine research

Hutch News Stories | Sabin Russell | June 4, 2020

Join Drs. Larry Corey and John Mascola for a discussion on COVID-19 vaccines

Hutch News Releases | June 4, 2020

Fred Hutch, NIH experts outline plan for COVID-19 vaccines

Hutch News Releases | May 11, 2020

Promising HIV vaccine fails to show efficacy, trial halted

Hutch News Stories | Sabin Russell | Feb. 4, 2020


Science on the horizon

Hutch News Stories | Susan Keown | Dec. 27, 2019

An old HIV vaccine surprises researchers once again

Hutch News Stories | Sabin Russell | Sept. 18, 2019

New HIV vaccine trial to launch in U.S., Latin America and Europe

Hutch News Stories | Sabin Russell | Jul. 17, 2019

Engineering vaccine-like protection without a vaccine

Hutch News Stories | Sabin Russell | May 18, 2019


Despite early rise, longterm ART decreases HSV shedding

Science Spotlight | B Traxinger | Dec. 17, 2018

'Cautiously optimistic' about HIV vaccines

Hutch News | Sabin Russell | Nov. 30, 2018
A conversation in advance of World AIDS Day with pioneering HIV researcher Dr. Larry Corey

Models aren’t just pretty

Science Spotlight | BL Debuysscher | Sept. 17, 2018

HVTN 100 clinical trial findings advance HIV vaccine research and development

VIDD News | Aziel Gangerdine | June 26, 2018
An HIV vaccine regimen tested in an early-phase clinical trial elicited robust immune responses that appeared to be stronger than those observed in a landmark 2009 study showing that a vaccine can protect people from HIV infection.

When scientific hypotheses don’t pan out

Hutch News | Rachel Tompa | Feb. 16, 2018
Research studies are often built around an educated guess. What happens when those guesses are wrong?


10 highlights of Fred Hutch science in 2017

Hutch News | Sabin Russell and Susan Keown | Dec. 28, 2017
A look back at notable discoveries in cancer immunotherapy, HIV prevention and more

New 'mosaic' HIV vaccine study launched for World AIDS Day

Hutch News | Mary Engel | Dec. 1, 2017
As lights around the world glow red today, Fred Hutch-based researchers lead global effort to end the pandemic

Stealing a secret from an unwelcome virus

Hutch News | Sabin Russell | June 29, 2017
An unexpected discovery in a herpes lab might bring relief to cancer patients

Cytomegalovirus causes transient prior to lifelong infection

Science Spotlight | BL DeBuysscher | May 15, 2017
Human cytomegalovirus (CMV) is a common virus that infects almost half of people over 40, usually causing no symptoms. 

Good News at Fred Hutch

Hutch News | Jan. 19, 2017
Dr. Larry Corey wins $2.6 million grant to explore using CAR T cells for HIV cure

Good News at Fred Hutch

Hutch News | Jan. 5, 2017
425 Magazine salutes Fred Hutch HIV researcher, community advocate


Experimental herpes drug more effective than standard treatment

Hutch News | Mary Engel | Dec. 20, 2016
Pritelivir reduces viral shedding and lesions better than valacyclovir, study shows

Good News at Fred Hutch

Hutch News | Nov. 4, 2016
Seattle magazine tabs Dr. Larry Corey for Seattle ‘Hall of Fame’

Can immunotherapy cure HIV?

Hutch News | Mary Engel | Aug. 8, 2016
A revolution in cancer care may offer clues to a cure or remission for HIV/AIDS

AIDS 2016: Faces and voices from an ongoing pandemic

Hutch News | Mary Engel | July 25, 2016
Beyond HIV treatment to vaccines and a cure, calls to finish the job — and leave no one behind

HIV vaccine clinical trials take center stage at world's largest global health conference

Hutch News | Mary Engel | July 20, 2016
'The HIV vaccine field is open for business,' said Fred Hutch's Dr. Larry Corey at International AIDS Society's biennial meeting in Durban, South Africa

Renewed hope for halting HIV through vaccine

Hutch News | Mary Engel | July 19, 2016
At International AIDS Conference, researchers are optimistic as two new HIV vaccine trials are set to explore different approaches for protection

Global AIDS conference returns to Africa: What's changed

Hutch News | July 18, 2016
The last time the International AIDS Conference was in Africa, AIDS denialism was at its height; two Fred Hutch leaders in the fight to end HIV talk about where we’ve been – and what’s next

Fred Hutch HIV cure program extended, expanded

Hutch News | Mary Engel | July 13, 2016
DefeatHIV receives second five-year grant from NIH to research gene and cell therapies

Good News at Fred Hutch

Hutch News | June 17, 2016
Dr. Larry Corey receives commissioned portrait

35 years in the AIDS trenches

Hutch News | Mary Engel | June 13, 2016
After helping pave the way to HIV treatment, Dr. Larry Corey wants a vaccine — and a cure

‘The miracle was you got to see some part of that person’s life’

Hutch News | Rachel Tompa | June 7, 2016
25 years after his death, infectious disease expert Dr. Joel Meyers honored at inaugural symposium in his name

Experimental HIV vaccine clinical trial to expand in South Africa

Hutch News | Mary Engel | May 18, 2016
Scientists give go-ahead for what could become the first licensed vaccine against the AIDS virus

A new path to an AIDS vaccine?

Hutch News | Mary Engel | Apr. 7, 2016
A ‘landmark’ clinical trial called the AMP study launches on three continents to test HIV-blocking super antibodies


Optimizing the benefits from HIV vaccines

VIDD News | Mindy Miner | Dec. 7, 2015
One hurdle in HIV vaccine development is because genetically distinguishable strains (clades) of HIV circulate in different areas of the globe.

‘Don’t stop now’: an endgame for HIV/AIDS

Hutch News | Mary Engel | Dec. 2, 2015
HBO’s ‘Countdown to Zero,’ featuring Fred Hutch researchers, shows the pandemic remains, but fresh hope abounds

Countdown to Zero: The path to an HIV vaccine

Hutch News | Mary Engel | Dec. 1, 2015
A World AIDS Day Q&A with Fred Hutch’s Dr. Larry Corey, featured in HBO special report

Findings on immune response inform direction of HIV vaccine development

Hutch News | Oct. 21, 2015
Study determines types of immune responses that an HIV vaccine may need to achieve protection against infection


Dr. Larry Corey steps down to return to his passion of hands-on science

Hutch News | Linda Dahlstrom | May 8, 2014
Building on career of life-saving research, Corey shifts full-time focus to the lab in quest for HIV and herpes vaccines, better cancer treatments

Cancer immunotherapy’s untapped potential inspires optimism

Hutch News | Dr. Sabrina Richards and Andrea Detter | Apr. 24, 2014
Xconomy Forum at Fred Hutch highlights excitement of recent progress, future promise

New anti-HSV-2 drug reduces genital viral shedding

VIDD News | Mindy Miner | Mar. 18, 2014
Thirty years ago, Seattle scientists were instrumental in demonstrating that the drug acyclovir was efficacious for curbing HSV-2 symptoms and promoting genital ulcer healing. 

HVTN 505 phase 2b HIV vaccine trial showed no efficacy to reduce HIV infection risk

VIDD News | Mindy Miner | Jan. 24, 2014
The research community has developed several biomedical and behavioral interventions for the prevention of HIV in the last six years.


HIV Vaccine Trials Network among five nationwide selected to receive seven-year award

Hutch News | Dec. 17, 2013
NIH funding will propel large-scale HIV vaccine clinical trials in South Africa and beyond

Leading cancer research centers team up to launch biotech startup focused on cancer immunotherapy

Hutch News | Dec. 4, 2013
Fred Hutch and Memorial Sloan-Kettering Cancer Center, along with pediatric partner Seattle Children’s Research Institute, have joined forces to launch Juno Therapeutics Inc., a new biotechnology company focused on bringing forward novel immunotherapies for cancer.

Influenza susceptibility: what’s your genotype?

VIDD News | Mindy Miner | Nov. 4, 2013
For unknown reasons, the pandemic A/H1N1 influenza virus (pH1N1) is more deadly in indigenous populations around the world than those of European/Caucasian descent.

Cape Town conference ends, 'grand endeavor' begins

Hutch News | Deborah Bach | Oct. 25, 2013
Week-long meeting, lab opening mark start of journey toward successful HIV vaccine, said Dr. Larry Corey

NIH saves lives: Fred Hutchinson Cancer Research Center calls on Congress to restore full NIH funding

Hutch News | May 15, 2013
Fred Hutch today called on Congress to support restoring full funding to the National Institutes of Health (NIH), which supports pioneering research that saves lives. 

Genital herpes-suppressing immune cells identified

Hutch News | Dean Forbes | May 9, 2013
Discovery by Dr. Larry Corey and colleagues has implications for development of vaccine to prevent and treat HSV-2, similar infections

2012 and earlier

Determining risk factors for CMV acquisition

VIDD News | Mindy Miner | Mar. 3, 2012
Approximately 1 million people in the United States are currently living with or in remission from hematologic malignancies, including leukemia, lymphoma and myeloma. 

Can high-dose antiherpes therapy eliminate genital HSV-2 shedding?

VIDD News | Mindy Miner | Jan. 5, 2012
Despite the efficacy of acyclovir and valacyclovir in reducing herpes genital lesions, antiviral therapy decreases the risk of transmission by only 48%. 

Does adeno-associated virus lead to clinical disease in the immunosuppressed?

VIDD News | Mindy Miner | Dec. 1, 2011
Adeno-associated virus (AAV) is a paravirus that has been considered an attractive candidate vaccine vector (or “delivery system”) due to its presumed nonpathogenicity and specific integration into the host’s DNA.

The consequences of antiviral therapy on herpesvirus shedding

VIDD News | Mindy Miner | Nov. 7, 2011
Herpes simplex virus 2 (HSV-2) is a sexually transmitted disease that can cause genital ulcers as a result of viral reactivation from a latent state.

The effect of antiviral compounds on human herpesvirus-8 replication

VIDD News | Stephen Voght | Oct. 3, 2011
Human herpesvirus-8 (HHV-8) is a human oncovirus and the key pathogenic agent in certain cancers: Kaposi sarcoma, primary effusion lymphoma and certain types of multicentric Castleman disease. 

Accelerating the pace of HIV clinical trials

VIDD News | Mindy Miner | Oct. 3, 2011
In the last 12 years, approximately 15 million new HIV infections occurred.

A test for the T cell immune response to HSV-2

VIDD News | Mindy Miner | Sept. 16, 2011
Herpesviruses are known for causing recurrent clinical episodes, usually in the form of a sore on the skin or genital surfaces.

Identifying ulcers

VIDD News | Sept. 5, 2011
A VIDD study has found that patients co-infected with HIV and genital herpes are not always aware of herpes-induced ulcers, suggesting that new methods to prevent herpes and HIV transmission in this population are needed. 

The Phambili study: further insights into the Merck Ad5-based HIV vaccine

VIDD News | Rachel Tompa | July 11, 2011
The HVTN’s Step study, a large phase IIb trial to test the efficacy of a Merck adenovirus 5 (Ad5)-based HIV vaccine, was halted in 2007 when mid-trial analyses showed that the vaccine had no effect in preventing HIV infection.

T-cell responses to HIV proteins are biased toward variable sequences

VIDD News | Stephen Voght | June 10, 2011
An effective HIV vaccine designed to elicit T-cell responses must either induce broad responses to a wide variety of epitopes, or protein pieces, in order to cover the extensive sequence variability in circulating HIV-1 strains, or it must be focused on a few highly conserved epitopes expected to be present in the majority of circulating strains likely to be encountered by a vaccinated individual. 

Safety and immunogenicity of a DNA/adenovirus serotype 5 HIV-1 Env/Gag/Pol/Nef vaccine

VIDD News | Stephen Voght | June 6, 2011
A major obstacle to the development of an effective HIV vaccine is the high genetic diversity among global HIV-1 isolates, most notably in the envelope protein (Env) that makes up the virus’ outer shell. 

Fred Hutchinson Cancer Research Center announces selection of its new president and director

Hutch News | July 30, 2010
The Fred Hutch board of trustees today announced the selection of Lawrence Corey, M.D., an internationally renowned expert in virology, immunology and vaccine development, as its new president and director.

Hutchinson Center grows to five scientific divisions

Hutch News | July 6, 2010
The three-year-old Vaccine and Infectious Disease Institute at Fred Hutchinson Cancer Research Center has become the Hutchinson Center's fifth scientific research division and has been renamed the Vaccine and Infectious Disease Division (VIDD).

Dr. Larry Corey named new member of the Institute of Medicine

Hutch News | Oct. 13, 2008
Larry Corey, M.D., senior vice president and co-director of the Vaccine and Infectious Disease Institute at Fred Hutchinson Cancer Research Center, today was named as one of 65 new members of the prestigious Institute of Medicine (IOM).

Hutchinson Center establishes new vaccine and infectious disease institute

Hutch News | May 1, 2007
Fred Hutch has established a new Vaccine and Infectious Disease Institute to develop and implement prevention strategies for globally important infectious diseases, including HIV, malaria and cancer.

NEJM editorial: More needs to be done to diagnose and treat genital herpes infections in HIV-infected persons

Hutch News | Feb. 21, 2007
The association between genital herpes and higher viral loads of HIV-1 in HIV-infected persons is strong enough to warrant more routine testing for the herpes virus in HIV-positive patients, as well as additional clinical studies of the co-infections, according to an editorial to be published in the Feb. 22 New England Journal of Medicine.

Antiviral Drug Reduces Genital Herpes Transmission Between Sexual Partners By 50 Percent

Hutch News | Dec. 31, 2003
An international team of researchers finds that taking a single daily dose of an approved antiviral drug known as valacyclovir can reduce the transmission of genital herpes to uninfected partners by 50 percent.

Fred Hutchinson Cancer Research Center Named as Core Operations Center for Worldwide HIV Vaccine Trials Network

Hutch News | May 25, 2000
The National Institute of Allergy and Infectious Diseases announced today the formal establishment of a worldwide HIV Vaccine Trials Network (HVTN).

NIAID Creates Global Network to Advance Development of HIV Vaccines

Hutch News | May 25, 2000
The worldwide search for an HIV vaccine received a boost today as the National Institute of Allergy and Infectious Diseases (NIAID) announced funding of nine U.S. clinical units of the new HIV Vaccine Trials Network (HVTN).